Brokers Set Expectations for Reviva Pharmaceuticals Holdings, Inc.’s Q1 2024 Earnings (NASDAQ:RVPH)

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) – Equities research analysts at HC Wainwright cut their Q1 2024 EPS estimates for shares of Reviva Pharmaceuticals in a research report issued to clients and investors on Monday, April 22nd. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings of ($0.28) per share for the quarter, down from their previous estimate of ($0.27). HC Wainwright has a “Buy” rating and a $20.00 price target on the stock. The consensus estimate for Reviva Pharmaceuticals’ current full-year earnings is ($0.92) per share. HC Wainwright also issued estimates for Reviva Pharmaceuticals’ Q3 2024 earnings at ($0.24) EPS, Q4 2024 earnings at ($0.30) EPS, FY2024 earnings at ($1.04) EPS and FY2025 earnings at ($1.09) EPS.

Separately, Benchmark reissued a “speculative buy” rating and issued a $17.00 target price on shares of Reviva Pharmaceuticals in a research note on Tuesday, April 16th.

Reviva Pharmaceuticals Price Performance

Shares of RVPH stock opened at $3.06 on Wednesday. The firm has a 50-day moving average price of $3.60 and a 200 day moving average price of $4.11. Reviva Pharmaceuticals has a twelve month low of $2.67 and a twelve month high of $9.25.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Vontobel Holding Ltd. acquired a new position in shares of Reviva Pharmaceuticals during the 4th quarter valued at about $72,000. EMC Capital Management increased its stake in shares of Reviva Pharmaceuticals by 1,294.3% during the 3rd quarter. EMC Capital Management now owns 123,915 shares of the company’s stock valued at $613,000 after acquiring an additional 115,028 shares during the last quarter. Finally, Armistice Capital LLC increased its stake in shares of Reviva Pharmaceuticals by 194.0% during the 4th quarter. Armistice Capital LLC now owns 1,764,000 shares of the company’s stock valued at $9,085,000 after acquiring an additional 1,164,000 shares during the last quarter. Institutional investors and hedge funds own 63.18% of the company’s stock.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals Holdings, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is brilaroxazine (RP5063), which is in Phase III clinical trials for use in the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis.